56
Participants
Start Date
January 31, 2015
Primary Completion Date
September 27, 2019
Study Completion Date
September 27, 2019
Victoza (liraglutide) with dietician monitoring
Victoza (liraglutide), an FDA-approved medication, is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Subjects with this intervention will be followed by the MD and dietician throughout the study to monitor progress through 4 week period of weight maintenance and 8 week period of weight loss.
Placebo with dietician monitoring
Subjects will not receive the study drug, but will be followed by the MD and dietician throughout the study to monitor progress through 4 week period of weight maintenance and 8 week period of weight loss.
Freidenrich Center for Translational Research (FCTR), Stanford
Stanford University
OTHER